Online inquiry

IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10411MR)

This product GTTS-WQ10411MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10411MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14588MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ10524MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ3574MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ9369MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ8102MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ14520MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ11018MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ5999MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW